

*Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the prospectus dated 9 October 2025 (the “**Prospectus**”) of Fujian Haixi Pharmaceuticals Co., Ltd. (the “**Company**”) incorporated in Hong Kong with limited liability.*

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for any securities. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Global Offering described below before deciding whether or not to invest in the Offer Shares.

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia) or any other jurisdiction where such distribution is prohibited by law. This announcement does not constitute and is not an offer to sell or a solicitation of any offer to buy securities in Hong Kong, the United States or elsewhere. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “**U.S. Securities Act**”) or any state securities laws of the United States and may not be offered, sold, pledged or transferred within the United States or to or for the account or benefit of U.S. persons, except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act. There will be no public offering of securities of the Company in the United States.*

Potential investors of the Offer Shares should note that the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the paragraph headed “Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Grounds for Termination of the Hong Kong Underwriting Agreement” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date.



Fujian Haixi Pharmaceuticals Co., Ltd.

福建海西新藥創制股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2637)

DELAY IN LISTING TIMETABLE

Reference is made to the Prospectus of the Company dated 9 October 2025.

According to the Prospectus, an announcement containing information regarding the final Offer Price, the level of indication of interest in the International Placing, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares shall be published by no later than 8:00 a.m. on Friday, 17 October 2025 (the “**Announcement**”).

The board of directors (the “**Board**”) would like to announce that additional time is necessary to finalise the Announcement and to obtain clearance from the regulators, so there will be a delay in the listing timetable of the Company. The Board will update the market as soon as practicable.

By order of the Board
Fujian Haixi Pharmaceuticals Co., Ltd.
福建海西新藥創制股份有限公司
Dr. Kang Xinshan
Chairman and Executive Director

Hong Kong, 16 October, 2025

Directors of the Company named in the application to which this announcement relates are: (i) Dr. Kang Xinshan, Ms. Feng Yan, Dr. Chen Guangming and Dr. Chen Shuyi as executive Directors; (ii) Mr. Xu Dong and Mr. Wang Xinkun as non-executive Directors; and (iii) Mr. Gong Weimin, Ms. Wang Shanshan and Ms. Pu Meiting as independent non-executive Directors.

This announcement is available for viewing on the Company's website at <https://hxpharma.com/index.html> and the Stock Exchange's website at www.hkexnews.hk.